Spots Global Cancer Trial Database for Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Official Title: Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Study ID: NCT00580320
Interventions
Study Description
Brief Summary: Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.
Detailed Description: The primary objective is to determine recommended phase II doses for the combination dacarbazine and bortezomib administered weekly. Secondary objectives are to determine the maximum tolerated dose combination and to observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Massey Cancer Center/Virginia Commonwealth University, Richmond, Virginia, United States
Contact Details
Name: Andrew Poklepovic, MD
Affiliation: Massey Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
